Arivin Therapeutics is a preclinical stage biotechnology company developing novel small molecule therapeutics for antimicrobial resistant gram negative infections in Cystic Fibrosis, bronchiectasis, COPD, sepsis and chronic wounds. Our team has developed a deep understanding of bacterial virulence inhibition with compounds that act via a dual acting mechanism: quorum quenching and LPS disruption. We are committed to develop and bring this new type of anti-infective class available to patients to tackle one of the most daunting crises the world is facing – antimicrobial resistance.
Using novel chemistry to disarm bacteria of their weapons and strip them from their armour, the Arivin's lead molecules' dual mechanism of action targets bacterial infections without killing the bacteria or stopping its growth.
Due to reduced selection pressure, the non-bactericidal virulence inhibition is less likely to confer resistance. The compounds increase the potency of traditional antibiotics and reduce target bacteria's resistance. Importantly, the mechanism reduces expression of toxins which reduces inflammation and tissue damage at the site of infection.